Parkinson's disease. It has been postulated that mitochondrial respiratory failure and oxidative stress are two major contributors to nigral cell death in Parkinson's disease. Loss ofmitochondrial complex I and the a-ketoglutarate dehydrogenase complex in the substantia nigra has been reported. Evidence to indicate oxidative stress includes a high dopamine content, increase in superoxide dismutase activities, increase in iron, and decrease in glutathione in the substantia nigra. The question posed is which one occurs first. We believe mitochondrial respiratory failure occurs first, because slowing down of the electron transport induces an increase in the formation of activated oxygen species. The primary cause of Parkinson's disease is still unknown, but we believe the interaction of environmental toxins and genetic predispositions is important. In this respect, molecular genetic studies on familial Parkinson's disease are very important.
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Introduction
Parkinson's disease was first described by James Parkinson in 1817 (1). The disease is characterized clinically by resting tremor, cogwheel rigidity, akinesia, and loss of righting reflex, and pathologically by selective degeneration of the pigmented nuclei of the brain stem, i.e., the substantia nigra and the locus coeruleus; although degeneration of the dorsal motor nucleus of the vagal nerve, the pedunculopontine nucleus (2), and the substantia innominata (3) has also been reported in Parkinson's disease, degeneration of the substantia nigra and the locus coeruleus is the constant and the most severe finding. Another characteristic is the presence of Lewy bodies in the remaining neurons; Lewy bodies are the intracytoplasmic eosinophilic inclusions with a pale halo surrounding the core in hematoxylineosin staining.
Within the substantia nigra, ventrolateral part is usually most severely affected (4), and this part mainly projects to putamen. The medial substantia nigra mainly projecting the caudate nucleus is less involved and is believed to be related to cognitive functions (5). Severe lesion in the rostral dorsomedial part of the substantia nigra may be the cause of cognitive d ysfunction and/or dementia (6).
The annual incidence rate of parkinsonism has not changed for many years; it was estimated to be approximately 20.5 per 1 00,000 population in Rochester, Minnesota; among them 86% had Parkinson's disease (7). The prevalence of Parkinson's disease among white people has been variously reported from 106 to 201 per 100,000 population (8). The prevalence rate in Japan is 80.6 per 100,000 population (9), and in China 57 per 100,000 population (10). Usually Parkinson's disease has its onset in the fifth decade or later; the peak age of onset is between 55 and 65, but the age of onset ranges from 20 to 80 years. Patients with age of onset under 40 years have been grouped as juvenile parkinsonism (1 1) or young onset parkinsonism (1.2). Most of the late onset patients are sporadic; concordance rate among homozygotic twins is low (13). However, familial occurrence is not rare among patients with the onset of age under40 years. Drug therapy ofParkinson' s disease has achieved a great success, and the life expectancy of patients with Parkinson's disease has become very close to that of the general population ( 14), however, numerous problems may arise from the long-term drug treatment. To overcome those problems, elucidation of the etiology ofParkinson's disease and development of drugs which can protect nigral neurons from degeneration are mandatory. Here, we review the etiology and pathogenesis of Parkinson's disease and the recent progress in the treatment of Parkinson's disease.
Etiology and Pathogenesis of Parkinson's Disease

MPTP-induced parkinsonism
The recent progress on the etiology and pathogenesis of Parkinson's disease has been greatly dependent upon the discovery of MPTP-induced parkinsonism. MPTP (l-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine), a meperidine analog, was found as a contaminant ofa home-madeillicit narcotic ( 15, 16) . People who injected MPTP-contaminated narcotic drugs developed severe parkinsonism with selective degeneration in the substantia nigra (15) (16) (17) .
Langston et al (16) (76) found a significant loss of glutathione in the substantia nigra, however, complex I activity, although it was reduced, did not reach statistical significance, and the loss of complex I activity was slightly less than that of glutathione (75). Based on these findings, they concluded that oxidative stress occurs first in Parkinson's disease, and that respiratory failure is secondary to oxidative stress.
Wefeel the reverse is true because not only complex I but also the a-ketoglutarate dehydrogenase complex is reduced in Parkinson's disease (40). The reduction in state 3 respiration from the dual loss of complex I and a-ketoglutarate dehydrogenase complex is far greater than that from loss of complex I alone, and it may exceed the loss of glutathione.
Furthermore, it has been shown that mitochondria produce free radicals such as superoxide anions (79) 
Familial and Juvenile Parkinsonism
As the primary cause of Parkinson's disease is still unknown, molecular genetic studies on familial patients with Parkinson's disease are very important. Patients with parkinsonism with the age of onset before the age of 40 are usually grouped as juvenile parkinsonism (ll, 107) or early onset parkinsonism ( 1 2); Quinn et al ( 1 2) proposed to reserve the term "juvenile" to those patients with the age of onset before 20 years. Familial incidence among early onset parkinsonism is much higher than that among late onset patients; the familial incidence may be as high as 40% (107). Early onset parkinsonism is not a single disease entity, but a group of disorders with different modes of inheritance; the following familial types have been reported. Lewy body-positive familial Parkinson 's disease This is the most common form offamilial parkinsonism. The age of onset is usually between 30 and 40 years of age, however, onset before 30 years and after 40 years is also known. Autosomal dominant inheritance appears to be more common ( 1 08-1 10), but autosomal recessive forms also exist (1 1 1 Koller et al (120) . The question of whether or not the use oflevodopa should be delayed until the advanced stage of Parkinson's disease has long been debated, however, the current trend appears to be starting levodopa treatment whenever the patient starts to show difficulty in moving in ordinary daily living or there is threat of losing his jobs. In our opinion, the use oflevodopa should not be delayed intentionally.
Motor fluctuations from long-term levodopa treatment is a big problem. Newer drugs have been developed to decrease the severity and the incidence of motor fluctuations. Among the newly developed dopamine agonists, cabergoline is a new D2 receptor agonist of an ergot compound with an extremely long half-life of about 65 hours (121), and it was reported to have reduced the mean percentage "off" time by 31% in one report (122). Talipexol is a presynaptic dopamine agonist as well as a potent post-synaptic D2 receptor agonist when the dopaminergic terminals are degenerated ( 1 23) ; the incidence ofgastrointestinal side effects tends to be lower with this than with the conventional dopamine agonists ( 1 24). Deprenyl, a selective monoamine oxidase B inhibitor, is also effective in reducing the "off" time of motor fluctuations; Golbe et al (125) reported 56% increase d hourly self-assessed gait disturbance of fluctuating Parkinson's disease patients; levodopa dose was also reduced by 17% in their study.
Catechol-O-methyltransferase (COMT) inhibitors appear to be promising adjunctive treatment for symptom fluctuations of advanced Parkinson's disease. A fair amount of levodopa is metabolized to 3-O-methyldopa by COMT in systemic organs, and 3-<9-methyldopa may interfere with the transport of levodopa to brain. Concomitant use of a COMT inhibitor with levodopa increases the bioavailability of levodopa to the brain The effect of stereotaxic thalamotomy has been well established for tremor and rigidity.
Drug-resistant tremor patients are good candidate for stereotaxic thalamotomy. The nucleus intermedius is the target for tremor and the nucleus ventrolateralis the target for rigidity (134). Thalamic stimulation is also effective in alleviating tremor (135). Recently, posterolateral pallidotomy has been found to be effective for drug-resistant gait disturbance, akinesia, and motor fluctuations (136). This new finding is based on the recent progress in neurophysiology of the basal ganglia. Two pathways, the indirect and the direct, have been shown to exist between the striatum and the internal segment of the globus pallidus (137); the indirect pathway originates mainly in the GABA-enkephalin neurons in the striatum and they change neurons in the external segment of the globus pallidus and in the subthalamic nucleus ending in the internal segment of the globus pallidus.
The loss of striatal dopamine ends up with a marked increase in the activity of glutamatergic neurons in the subthalamic nucleus, and this increased excitatory input to GABAergic neurons in the internal segment of the globus pallidus strongly inhibits thalamic neurons causing severe akinesia (136). 
